Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

Modern anticoagulation therapy has dramatically reduced the risk of stroke and systemic
thromboembolism in people with atrial fibrillation (AF). However, AF still impairs quality of …

Purpose Pharmacodynamic drug-drug interactions (PD DDIs) may influence the safety of
non-vitamin K antagonist oral anticoagulants (NOACs), but the extent to which PD DDIs …

Hypertension is globally the most common independent risk factor for atrial fibrillation.
Patients with hypertension have a 1.5–2.0 times higher risk of atrial fibrillation, which occurs …

Anticoagulants are a cornerstone of treatment in atrial fibrillation. Nowadays, direct oral
anticoagulants (DOACs) are extensively used for this condition in developed countries …

Background This systematic review assesses the likelihood of developing dementia and
cognitive impairment in patients with atrial fibrillation (AF) receiving non-vitamin K antagonist …

Patients aged≥ 65 years not only account for the majority of patients with atrial fibrillation
(AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity …

Background While treatment interruption of non-vitamin K antagonist oral anticoagulants
(NOACs) for elective surgery or procedures among patients with atrial fibrillation (AF) is …

The consensus guidelines of the Geriatric Society of Chinese Medical Association (GSCMA)
on the management of atrial fibrillation (AF) in the elderly was first published in 2011 and …

Polypharmacy, intended as the concomitant intake of five or more drugs, 1 is commonly
reported in the general population and particularly among older individuals. 2 Importantly …